Supplementary Files
Keywords
Perinatal morbidity and mortality
Pregnancy Outcome
Retrospective Studies
How to Cite
Abstract
Objective: To compare the frequency of live births in patients with BOH taking LMWH daily versus alternate days.
Methods: This was a randomised controlled trial, conducted at the Department of Obstetrics and Gynaecology, at POF Hospital, Wah, from 1st of January to 31st of December 2024. This study included 122 women aged 30-45 years with a history of adverse obstetric outcomes. Participants were randomly assigned to receive 40 mg low molecular weight heparin (LMWH) either daily (Group A Control) or on alternate days (Group B Experimental) starting in first trimester at enrolment visit when fetal cardiac activity becomes positive, with follow-ups assessing compliance, symptoms, and fetal well-being through history and ultrasound. Live birth was the primary outcome. Data analysis was performed using SPSS v. 22, with p-values <0.05 considered statistically significant.
Results: The mean age was 34.90 ± 2.56 years, and the mean gestational age at enrolment was 9.95 ± 1.14 weeks. Among them, 46.7% underwent Spontaneous vaginal delivery, 39.3% Cesarean section, and 13.9% Evacuation and curettage, with 76.2% resulting in live births and 27.9% of newborns requiring Neonatal intensive care admission. No significant differences were observed between groups in terms of age, gestational age, mode of delivery, live birth frequency (p = 0.832), or Intrauterine death rates (p = 0.543). However, Neonatal intensive care unit admissions were significantly higher in the control group (p = 0.043).
Conclusion: The study found no significant difference between the two groups in terms of live births. However, neonatal intensive care unit admissions were significantly higher in the women receiving a daily low molecular weight heparin dose.
References
Iqbal Z, Jilanee SDA, Uppada LP, Imtiaz S, Khan H, Shah SMH, et al. Evaluating the Clinical Risk Factors Associated With Miscarriages in Women in Karachi, Pakistan. Cureus. 2021;13(10):e19057. https://doi.org/10.7759/cureus.19057.
Habets DHJ, Pelzner K, Wieten L, Spaanderman MEA, Villamor E, Al-Nasiry S. Intravenous immunoglobulins improve live birth rate among women with underlying immune conditions and recurrent pregnancy loss: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2022;18(1):23. https://doi.org/10.1186/s13223-022-00660-8.
Coomarasamy A, Harb HM, Devall AJ, Cheed V, Roberts TE, Goranitis I, et al. Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. Health Technol Assess. 2020;24(33):1-70. https://doi.org/10.3310/hta24330.
Wang G, Zhang R, Li C, Chen A. Evaluation of the effect of low molecular weight heparin in unexplained recurrent pregnancy loss: a meta-analysis of randomized controlled trials. J Matern Fetal Neonatal Med. 2022;35(25):7601-08 https://doi.org/10.1080/14767058.2021.1957819.
Dasari P, Suganya G. Outcome of Index Pregnancy in Women with Recurrent Pregnancy Loss (RPL). J Obstet Gynaecol India. 2022;72(Suppl 1):152-58. https://doi.org/10.1007/s13224-021-01598-4.
Bremme K, Lannemyr A, Tyni L, Chaireti R. Obstetric and neonatal outcomes in pregnant women treated with high-dose thromboprophylaxis: a retrospective, single-centre study. The Journal of Maternal-Fetal & Neonatal Medicine. 2021 May 19;34(10):1641. https:// doi.org10.1080/14767058.2019.1644312
Awolumate OJ, Kang A, Khokale R, Cancarevic I. Role of Low Molecular Weight Heparin in the Management of Unexplained Recurrent Pregnancy Loss: A Review of Literature. Cureus. 2020;12(10):e10956.
https://doi.org/10.7759/cureus.10956.
Beksac MS, Tanacan A, Ozten G, Cakar AN. Low-dose low-molecular-weight heparin prophylaxis against obstetrical complications in pregnancies with metabolic and immunological disorder-associated placental inflammation. J Matern Fetal Neonatal Med. 2022;35(8):1546-53. https://doi.org/10.1080/14767058.2020.1760834.
Dal Y, Naziroglu M, Ozkaya MO. Low molecular weight heparin treatment reduced apoptosis and oxidative cytotoxicity in the thrombocytes of patients with recurrent pregnancy loss and thrombophilia: Involvements of TRPM2 and TRPV1 channels. J Obstet Gynaecol Res. 2023;49(5):1355-65. https://doi.org/10.1111/jog.15612.
Wu XM, Li YX, Zheng HS, Zhou XT, Ke Y, Liu XP, Kang XM. The effect and mechanism of low-molecular-weight heparin on the decidualization of stromal cells in early pregnancy. J Matern Fetal Neonatal Med. 2024;37(1):2294701. https://doi.org/10.1080/14767058.2023.2294701.
Chen J, Huai J, Yang H. Low-molecular-weight heparin for the prevention of preeclampsia in high-risk pregnancies without thrombophilia: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2024;24(1):68.
https://doi.org/10.1186/s12884-023-06218-9.
Cruz-Lemini M, Vazquez JC, Ullmo J, Llurba E. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis. Am J Obstet Gynecol. 2022;226(2S):S1126-S44 e17. https://doi.org/10.1016/j.ajog.2020.11.006.
Scarrone M, Salmeri N, Buzzaccarini G, Canti V, Pasi F, Papaleo E, et al. Low-molecular-weight heparin in the prevention of unexplained recurrent miscarriage: a systematic review and meta-analysis. Sci Rep. 2024;14(1):14168. https://doi.org/10.1038/s41598-024-62949-5.
Mohammad-Akbari A, Mohazzab A, Tavakoli M, Karimi A, Zafardoust S, Zolghadri Z, et al. The effect of low-molecular-weight heparin on live birth rate of patients with unexplained early recurrent pregnancy loss: A two-arm randomised clinical trial. J Res Med Sci. 2022;27(78. https://doi.org/10.4103/jrms.jrms_81_21.
Ak M, Demir B, Cundubey CR, Cam S. Evaluation of Low-Molecular-Weight Heparin Treatment on First- and Second-Trimester Screening Test Results. Cureus. 2023;15(2):e35137. https://doi.org/10.7759/cureus.35137.
He S, Liang L, He S. Comparison of Low Molecular Weight Heparin Used alone or Combined with Aspirin in the Treatment of Fetal Growth Restriction. J Coll Physicians Surg Pak. 2022;32(9):1228-29. https://doi.org/10.29271/jcpsp.2022.09.1228.
Karadag C, Akar B, Gonenc G, Aslancan R, Yilmaz N, Caliskan E. Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation. J Matern Fetal Neonatal Med. 2020;33(11):1934-39. https://doi.org/10.1080/14767058.2019.1671348.
Zheng L, Xia B, Yuan Y, Wang Y, Wang Y. Low-molecular-weight heparin in addition to low-dose aspirin for preventing preeclampsia and its complications: A systematic review and meta-analysis. Front Cardiovasc Med. 2022;9(1073148. https://doi.org/10.3389/fcvm.2022.1073148.
Huang W, Yu Y, Chen L, Tang X, Fang X, Ou X, Du X. Comparative effectiveness of Low Molecular Weight Heparin on Live birth for Recurrent Spontaneous Abortion: systematic review and network meta-analysis: Effectiveness of LMWH on Live Birth in RSA. Am J Obstet Gynecol MFM. 2024;101572. https://doi.org/10.1016/j.ajogmf.2024.101572.
Mu F, Wang M, Huang J, Wang F. Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2023;287(29-35. https://doi.org/10.1016/j.ejogrb.2023.05.031.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2025 Rubina Malik, Kinza Alam, Asma Nafisa